BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25937178)

  • 1. Oxidative stress in paroxysmal nocturnal hemoglobinuria and other conditions of complement-mediated hemolysis.
    Fibach E; Dana M
    Free Radic Biol Med; 2015 Nov; 88(Pt A):63-9. PubMed ID: 25937178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative status of red blood cells, neutrophils, and platelets in paroxysmal nocturnal hemoglobinuria.
    Amer J; Zelig O; Fibach E
    Exp Hematol; 2008 Apr; 36(4):369-77. PubMed ID: 18261835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel therapeutic agents for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(9):884-891. PubMed ID: 37793862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
    Risitano AM
    Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
    DeZern AE; Brodsky RA
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pharmacology in complement-mediated hemolytic disorders.
    Bortolotti M; Barcellini W; Fattizzo B
    Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel anti-complement therapeutics for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation.
    Kurita N; Obara N; Fukuda K; Nishikii H; Sato S; Inagawa S; Kurokawa T; Owada Y; Ninomiya H; Chiba S
    Blood Coagul Fibrinolysis; 2013 Sep; 24(6):658-62. PubMed ID: 23917586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
    Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
    Front Immunol; 2020; 11():1460. PubMed ID: 32793201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement in hemolytic anemia.
    Brodsky RA
    Hematology Am Soc Hematol Educ Program; 2015; 2015():385-91. PubMed ID: 26637747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin.
    Ninomiya H; Kawashima Y; Nagasawa T
    Br J Haematol; 2000 Jun; 109(4):875-81. PubMed ID: 10929045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxysmal nocturnal hemoglobinuria.
    Parker CJ
    Curr Opin Hematol; 2012 May; 19(3):141-8. PubMed ID: 22395662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement in hemolytic anemia.
    Brodsky RA
    Blood; 2015 Nov; 126(22):2459-65. PubMed ID: 26582375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of complement inhibition in PNH.
    Hillmen P
    Hematology Am Soc Hematol Educ Program; 2008; ():116-23. PubMed ID: 19074068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.